AHA 2024 - Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. “BROOKLYN shows us that we get many more patients with FH to treatment targets by adding the CETP inhibitor obicetrapib to their therapy”, says Stephen Nicholls.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. “BROOKLYN shows us that we get many more patients with FH to treatment targets by adding the CETP inhibitor obicetrapib to their therapy”, says Stephen Nicholls.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
AHA 2024 - Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. “BROOKLYN shows us that we get many more patients with FH to treatment targets by adding the CETP inhibitor obicetrapib to their therapy”, says Stephen Nicholls.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Stay current with the best on medical education
